How does royalty financing work as an alternative funding mechanism, and what types of assets generate suitable royalty streams?

Royalty financing provides upfront capital in exchange for a percentage of revenue generated by a specific asset — typically intellectual property, a patent, a drug, a mineral resource, or a brand license. Unlike revenue-based financing (which draws from total company revenue), royalty financing is tied to a particular product or asset's performance.\n\nKey Distinction from RBF:\n\n| Feature | Revenue-Based Financing | Royalty Financing |\n|---|---|---|\n| Revenue base | Entire company revenue | Specific asset/product |\n| Duration | Until cap reached | Often perpetual or life-of-asset |\n| Cap on payments | Yes (fixed multiple) | Varies (may be uncapped) |\n| Asset specificity | Low (general business) | High (named product/patent) |\n| Typical sectors | SaaS, e-commerce | Pharma, mining, music, franchising |\n\nWorked Example:\nDawnbreak Pharma developed a specialty dermatology drug (Veridex) with FDA approval and $38 million in annual sales. They need $60 million to fund a new oncology pipeline but don't want to dilute equity or burden the balance sheet with traditional debt.\n\nCrestline Royalty Partners purchases a 4.5% royalty on Veridex net sales for $60 million.\n\nProjected returns for Crestline:\n\n| Year | Veridex Sales | Royalty (4.5%) | Cumulative Received |\n|---|---|---|---|\n| 1 | $42M | $1.89M | $1.89M |\n| 3 | $58M | $2.61M | $7.14M |\n| 5 | $72M | $3.24M | $14.25M |\n| 10 | $95M | $4.28M | $33.60M |\n| Patent expiry (Yr 14) | $45M (generic entry) | $2.03M | $52.80M |\n\nIf Veridex sales meet projections, Crestline earns $52.8M over 14 years on a $60M investment — an apparent loss. But Crestline modeled a bull case where Veridex expands into three new indications, pushing cumulative royalties to $94M and generating a 7.2% IRR.\n\nBest Asset Characteristics for Royalty Financing:\n1. Proven revenue stream: Asset already generating measurable cash flows\n2. Predictable demand: Patent-protected products, essential minerals, established franchises\n3. Limited ongoing capex: The royalty covers revenue, not profit, so high-margin assets work best\n4. Transparent measurement: Revenue must be independently verifiable and contractually defined\n\nInvestor Risks:\n- Product-specific risk: a drug recall, mine closure, or technology obsolescence kills the royalty stream\n- No operational control: the asset owner makes all business decisions\n- Revenue measurement disputes: definitions of \"net sales\" can vary (gross vs. net of returns, discounts, co-pay assistance)\n\nExplore royalty and alternative financing in our CFA Alternative Investments course.